ZAVEDOS Capsules (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Zavedos 5 mg Capsules.
Qualitative and quantitative composition
Idarubicin Hydrochloride 5.0 mg HSE.
Pharmaceutical form
Opaque red cap and body, self-locking, hard gelatin capsules, size no. 4, containing an orange powder.
Therapeutic indications
Whenever intravenous idarubicin hydrochloride cannot be employed e.g. for medical, psychological or social reasons, oral idarubicin can be used for remission induction in patients with previously untreated, ...
Posology and method of administration
Route of Administration Oral. Dosage is usually calculated on the basis of body surface area. In adult acute non-lymphocytic leukaemia (ANLL) also referred to as acute myelogenous leukaemia (AML), the ...
Contraindications
Hypersensitivity to idarubicin or to any of the excipients listed in section 6.1, other anthracyclines or anthracenediones Severe hepatic impairment Severe renal impairment Severe cardiomyopathy Uncontrolled ...
Special warnings and precautions for use
General Idarubicin should be administered only under the supervision of physicians experienced in the use of cytotoxic chemotherapy. This ensures that immediate and effective treatment of severe complications ...
Interaction with other medicinal products and other forms of interaction
Idarubicin is a potent myelosuppressant and combination chemotherapy regimens including other agents with similar action may be expected to induce additive myelosuppressant effects (see section 4.4). The ...
Fertility, pregnancy and lactation
Fertility Idarubicin can induce chromosomal damage in human spermatozoa. For this reason, males undergoing treatment with idarubicin should use effective contraceptive methods up to 3 months after treatment ...
Effects on ability to drive and use machines
The effect of idarubicin on the ability to drive or use machinery has not been systematically evaluated.
Undesirable effects
The frequencies of undesirable effects are based on the following categories: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), ...
Overdose
Very high doses of idarubicin may be expected to cause acute myocardial toxicity within 24 hours and severe myelosuppression within one to two weeks. Delayed cardiac failure has been seen with anthracyclines ...
Pharmacodynamic properties
Pharmacotherapeutic group: Anthracyclines and related substances ATC code: L01DB06 Idarubicin is an antimitotic and cytotoxic agent which intercalates with DNA and interacts with topoisomerase II and has ...
Pharmacokinetic properties
After oral administration to patients with normal renal and hepatic function, idarubicin is rapidly absorbed, with a peak time of 2-4 hours., is eliminated from systemic circulation with a terminal plasma ...
Preclinical safety data
No further preclinical safety data are available.
List of excipients
Microcrystalline cellulose Ph. Eur. Glyceryl palmito-stearate HSE Capsule shell: Red iron oxide (E172) FP Titanium dioxide (E171) Ph. Eur. Gelatin Ph. Eur. Sodium dodecyl sulfate Ph. Eur. Printing ink: ...
Incompatibilities
Not known.
Shelf life
Shelf life: 3 years.
Special precautions for storage
Store in a dry place.
Nature and contents of container
Type III amber glass bottles closed with an aluminium screw cap with a polyethylene gasket and a polyethylene cover cap. Aluminium/aluminium strips. Pack size: 1.
Special precautions for disposal and other handling
None stated.
Marketing authorization holder
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
Marketing authorization number(s)
PL 00057/1064
Date of first authorization / renewal of the authorization
10<sup>th</sup> May 2002
Date of revision of the text
08/2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
